பெண்ணோயியல் மற்றும் மகப்பேறியல் வழக்கு அறிக்கை திறந்த அணுகல்

சுருக்கம்

Treatment of Pustular Psoriasis with Infliximab during Pregnancy: Case Report and Review of the Literature

Yang Sun*, Nisha Suyien Chandran

Introduction: Infliximab is a chimeric monoclonal antibody to tumour necrosis factor alpha (TNF-α) inhibitor which crosses the placenta with resultant concerns regarding its use in pregnancy.

Case Report: A 31-year old Chinese lady with a history of generalized pustular psoriasis diagnosed at the age of 18 years old was admitted multiple times throughout her pregnancy for pustular psoriasis flare. After extensive discussion with the obstetricians and the patient, decision was made to continue infliximab throughout her pregnancy. A healthy female baby was delivered at 38 weeks of gestation had normal development and growth till the present age of 4 years old.

Conclusion: It is important to balance control of maternal pustular psoriasis with safety of the developing fetus during pregnancy. Inter-disciplinary management by dermatologists and obstetricians is vital to improve the quality of life of the mother and contribute to a favourable outcome for the fetus.